News
1don MSN
Vertex reiterates $11.85B–$12B 2025 revenue guidance while boosting JOURNAVX commercial investment
Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback